La Jolla Pharmaceutical Company (LJPC) Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension
7/9/2014 11:20:15 AM
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the Company plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH), a new indication. Initiation of this registration program is the result of a recent meeting between the Company and the U.S. Food and Drug Administration at which agreement was reached that blood pressure is an appropriate primary endpoint for approval.
Help employers find you! Check out all the jobs and post your resume.
comments powered by